CalciMedica (CALC) Competitors $2.00 +0.38 (+23.46%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.09 +0.09 (+4.45%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CALC vs. CHRS, ADAG, OCX, MGNX, ZNTL, CRBP, CLLS, ABVC, ORMP, and JMACShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Coherus Oncology (CHRS), Adagene (ADAG), OncoCyte (OCX), MacroGenics (MGNX), Zentalis Pharmaceuticals (ZNTL), Corbus Pharmaceuticals (CRBP), Cellectis (CLLS), ABVC BioPharma (ABVC), Oramed Pharmaceuticals (ORMP), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Its Competitors Coherus Oncology Adagene OncoCyte MacroGenics Zentalis Pharmaceuticals Corbus Pharmaceuticals Cellectis ABVC BioPharma Oramed Pharmaceuticals Maxpro Capital Acquisition Coherus Oncology (NASDAQ:CHRS) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Is CHRS or CALC more profitable? CalciMedica has a net margin of 0.00% compared to Coherus Oncology's net margin of -66.30%. Coherus Oncology's return on equity of 0.00% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets Coherus Oncology-66.30% N/A -26.51% CalciMedica N/A -171.81%-100.43% Do analysts prefer CHRS or CALC? Coherus Oncology presently has a consensus price target of $4.68, suggesting a potential upside of 432.20%. CalciMedica has a consensus price target of $16.00, suggesting a potential upside of 700.00%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts plainly believe CalciMedica is more favorable than Coherus Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67CalciMedica 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of CHRS or CALC? 72.8% of Coherus Oncology shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Comparatively, 41.6% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, CHRS or CALC? Coherus Oncology has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Which has preferable earnings and valuation, CHRS or CALC? Coherus Oncology has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus Oncology$266.96M0.38$28.51M-$1.13-0.78CalciMedicaN/AN/A-$13.70M-$1.56-1.28 Does the media favor CHRS or CALC? In the previous week, CalciMedica had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 4 mentions for CalciMedica and 2 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.94 beat CalciMedica's score of 0.72 indicating that Coherus Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCoherus Oncology beats CalciMedica on 9 of the 15 factors compared between the two stocks. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.94M$2.94B$5.55B$9.11BDividend YieldN/A2.42%5.07%4.01%P/E Ratio-1.2820.7128.2120.26Price / SalesN/A292.82432.0099.74Price / CashN/A42.1137.1257.67Price / Book1.877.638.045.49Net Income-$13.70M-$55.05M$3.19B$250.45M7 Day Performance23.53%8.43%3.63%4.79%1 Month Performance14.29%5.42%4.06%7.68%1 Year Performance-59.10%2.03%30.02%16.44% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica2.9037 of 5 stars$2.00+23.5%$16.00+700.0%-57.6%$27.94MN/A-1.2830Gap UpHigh Trading VolumeCHRSCoherus Oncology3.8068 of 5 stars$0.79+5.2%$4.68+496.4%-45.3%$91.04M$272.25M-0.69330News CoverageADAGAdagene2.5996 of 5 stars$1.93-1.0%$8.00+314.5%-29.5%$90.92M$100K0.00260OCXOncoCyte1.918 of 5 stars$3.18+16.3%$6.06+90.9%+0.8%$90.80M$3.84M-0.90120MGNXMacroGenics4.2543 of 5 stars$1.44+5.5%$5.71+298.2%-65.4%$90.53M$152.43M-1.61430News CoverageAnalyst UpgradeZNTLZentalis Pharmaceuticals2.2316 of 5 stars$1.26+5.5%$8.37+566.7%-66.6%$90.30M$67.43M-0.40160News CoveragePositive NewsCRBPCorbus Pharmaceuticals4.4819 of 5 stars$7.30+0.0%$50.88+596.8%-84.5%$89.36MN/A-1.7340Positive NewsCLLSCellectis3.4472 of 5 stars$1.60-0.3%$4.00+150.8%-20.9%$88.65M$49.22M-1.85290ABVCABVC BioPharma0.4089 of 5 stars$5.20+30.3%N/A+384.2%$88.30M$510K-40.0030News CoverageGap UpHigh Trading VolumeORMPOramed Pharmaceuticals1.0445 of 5 stars$2.12-1.9%N/A-14.5%$86.60M$1.34M-4.8210JMACMaxpro Capital AcquisitionN/A$6.44+4.9%N/A+2,720.4%$86.48MN/A0.002,021News Coverage Related Companies and Tools Related Companies Coherus Oncology Alternatives Adagene Alternatives OncoCyte Alternatives MacroGenics Alternatives Zentalis Pharmaceuticals Alternatives Corbus Pharmaceuticals Alternatives Cellectis Alternatives ABVC BioPharma Alternatives Oramed Pharmaceuticals Alternatives Maxpro Capital Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALC) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CALC Stock Alerts